Free press releases distribution network?

Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Promising Drugs for Non-Hodgkins Lymphoma May Change European Market Dynamics - New analysis from growth consulting company Frost & Sullivan, European Non-Hodgkin's Lymphoma Therapeutics Markets, finds that the market earned revenues of $2.2 billion in 2006 and estimates this to reach $7.2 billion in 2013
Promising Drugs for Non-Hodgkins Lymphoma May Change European Market Dynamics

 

PRZOOM - /newswire/ - London, United Kingdom, 2008/01/29 - New analysis from growth consulting company Frost & Sullivan, European Non-Hodgkin's Lymphoma Therapeutics Markets, finds that the market earned revenues of $2.2 billion in 2006 and estimates this to reach $7.2 billion in 2013.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The European non-Hodgkin's lymphoma (NHL) therapeutics market has been monopolised by MabThera for a number of years. Although CHOP chemotherapy is the major treatment for all forms of NHL, it is highly genericised with limited prospects for revenue growth. However, market dynamics are poised to change in the near future due to the anticipated launch of many promising pipeline drugs currently in phase 3 of their development.

New analysis from growth consulting company Frost & Sullivan (pharma.frost.com), European Non-Hodgkin's Lymphoma Therapeutics Markets, finds that the market earned revenues of $2.2 billion in 2006 and estimates this to reach $7.2 billion in 2013.

"The relapsing nature of NHL is creating the need for new therapeutic options," notes Frost & Sullivan Research Analyst Ranjith Gopinathan. "Though MabThera is very popular and has gained widespread acceptance, there still exists a high unmet need among NHL patients."

About 1.75 million people worldwide are living with NHL. As the risk of developing the disease increases with age, the rising life expectancy across Europe is leading to a growing demand for treatments.

MabThera is projected to retain its market leadership position over the next 5-6 years. Most drugs in the pipeline are being positioned as add-on combination therapies with MabThera or CHOP. The market is poised to accelerate from 2012 onwards, pushed by several promising drugs, currently in their phase 3 development stage.

"Add-on drugs, in combination with MabThera or chemotherapy, are a prospective market driver," states Gopinathan. "For instance, Favrille expects Favid to be a blockbuster when approved for commercialisation."

Most research-based biotechnology firms are however currently facing considerable losses. Moreover, stringent clinical and regulatory hurdles could curb potential returns from biotechnology products. For such companies, difficulties in securing resources to fund clinical trials will delay the development process and extend the time to market.

Companies such as Favrille and Genitope are facing mounting operating expenses due to high investments in research. Any regulatory setback could jeopardise their business sustainability.

Additionally, most oncologists are satisfied with MabThera and may not feel the need to replace it entirely with new drugs. Hence, combination drugs with MabThera or CHOP would gain easier acceptance among oncologists and patients.

"Big pharma should look for strategic alliances or acquisition of promising pipeline drugs," advises Gopinathan. "Small-sized biotechnology companies should focus on research and finding a suitable marketing partner."

If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants with an overview of the investment analysis and growth opportunities in the European Non-Hodgkin's Lymphoma Therapeutics Market, then send an email to Patrick Cairns, Corporate Communications, at patrick.cairns[.]frost.com, with your full name, company name, title, telephone number, fax number, and email address. Upon receipt of the above information, an overview will be sent to you by email.

European Non-Hodgkin's Lymphoma Therapeutics Markets is part of the Pharmaceutical & Biotechnology Growth Partnership Service Programme, which also includes research in the following markets: European Urinary Incontinence Therapeutics Markets, European Endometriosis Therapeutics Markets, Blockbusters Going Off-patent: Opportunities for Generics Manufacturers in Europe, European Osteoarthritis Market, European Head and Neck Cancer Therapeutics Markets and European Breast Cancer Therapeutics Markets. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.

About Frost & Sullivan
Frost & Sullivan, the Global Growth Consulting Company, partners with clients to accelerate their growth. The company's Growth Partnership Services, Growth Consulting and Career Best Practices empower clients to create a growth focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Promising Drugs for Non-Hodgkins Lymphoma May Change European Market Dynamics

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
Frost & Sullivan |
Contact: Patrick Cairns 
+27 83 258 4219 patrick.cairns[.]frost.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  JobsWare.com

Visit  La Bella Bakery Artisan Bakery Arizona

Visit  BizJobs.com







 
  ©2016 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today